var gArticleJson = { "fileId":"12239547", "version":"20200608210341", "title":"顺庆医保开出首张贝达喹啉批复单，为患者节省10万元！", "attAbstract":"", "publishtime":"2020-06-08 21:03:41", "source":"顺庆医保", "author":"", "editor":"", "liability":"", "subtitle":"", "headtitle":"", "columnID":"16599", "columnName":"首页~本地", "discussClosed":"0", "articleType":"0", "reporter":"", "countRatio":"3.4", "praiseDescription":"", "praiseAmount":"9.99", "praiseStatus":"0", "countClickInitial":"53", "countShareClick":"1", "countClick":"0", "countDiscuss":"0", "countPraise":"0", "countShare":"0", "copyright":"0", "exclusive":"0", "bookRackPic":"", "sharePic":"", "editorVersion":"1", "picTop":"", "imageUrl":"https://jrsqoss.newaircloud.com/jrsq/pic/202006/08/sdeb-5c208e144e7eee74e8804d7787-1e0e4e.png", "content":"

耐多药结核病被称为“长了翅膀的癌症”，是结核病治疗中的一大难题。2020年1月2日，耐多药结核病药物富马酸贝达喹啉（以下简称“贝达喹啉”）正式在我国上市。近日，顺庆医保局迎来首位报销 “贝达喹啉”费用的患者罗某林，并开出了我区第一张贝达喹啉的批复单。

患者罗某林了解到“贝达喹啉”为今年新增谈判特殊药品，且已纳入特药报销目录后，第一时间在成都市公共卫生临床医疗中心医院提交了认定申请表。经认定医生认定通过后，提交至顺庆区医保局，区医保局工作人员经过审核患者罗某林的认定资料符合医保用药报销后，第一时间为该患者出具相关批复。

据了解，患者罗某林于两年前在川北医学院确诊肺结核，抗痨治疗数月后产生耐药性。由于耐多药结核病的治疗选择方案数量有限且费用高昂，反复治疗会影响患者的生活质量，导致不少家庭因病致穷。现“贝达喹啉”纳入新增谈判特殊药品，治疗医生建议其使用贝达喹啉，100mg/片，每片350元，患者每天需服用400mg的剂量，持续服用168天产生的费用就高达235200元，通过医保审批报销该药品后，为患者减轻了10万元的经济负担，为患者带来了真正的实惠。


", "images":[ { "summary":"", "width":"550", "height":"398", "imageUrl":"https://jrsqoss.newaircloud.com/jrsq/pic/202006/08/b1f68eb5-d979-4778-9545-23cb36d9a62c.png" }, { "summary":"", "width":"1080", "height":"680", "imageUrl":"https://jrsqoss.newaircloud.com/jrsq/pic/202006/08/ee88e62e-294e-48d4-bd07-e40c17e7015f.png" }, ], "videos":[ ], "widgets":{ "pic":{ "title":"", "content":"", "list":[ ] }, "video":{ "title":"", "content":"", "url":"" }, "file":[ ] }, "related":[ ], "columnDescription":"", "columnKeyword":"", "columnIcon":"" }